ZNTL Zentalis Pharmaceuticals, Inc.
Healthcare$3.92+0.00%OpenMarket Cap: $279.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.56
P/S
0.00
EV/EBITDA
-2.14
DCF Value
$-0.12
FCF Yield
-43.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-53.6%
ROA
-49.1%
ROIC
-66.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-37.9M | $-35.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-37.4M | $-35.2M | $— | — |
| FY null | $0.00 | NaN% | $-152.8M | $-137.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-33.7M | $-26.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-36.1M | $-26.9M | $— | — |
| Q1 null | $0.00 | NaN% | $-45.6M | $-48.3M | $— | — |
| Q4 null | $26.9M | 100.0% | $-49.8M | $-47.5M | $— | — |
| FY null | $67.4M | 100.0% | $-191.2M | $-165.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-51.4M | $-40.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-65.1M | $-88.3M | $— | — |
| Q1 null | $40.6M | 99.2% | $-24.8M | $10.1M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-67.9M | $-60.9M | $-0.86 | — |